Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
dc.contributor.author | Buti, Maria | |
dc.contributor.author | Fung, Scott | |
dc.contributor.author | Gane, Edward | |
dc.contributor.author | Afdhal, Nezam H. | |
dc.contributor.author | Flisiak, Robert | |
dc.contributor.author | Flaherty, John F. | |
dc.contributor.author | Martins, Eduardo B. | |
dc.contributor.author | Yee, Leland J. | |
dc.contributor.author | Dinh, Phillip | |
dc.contributor.author | Bornstein, Jeffrey D. | |
dc.contributor.author | Subramanian, G. Mani | |
dc.contributor.author | Janssen, Harry L. A. | |
dc.contributor.author | George, Jacob | |
dc.contributor.author | Marcellin, Patrick | |
dc.contributor.buuauthor | Gürel, Selim | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 7003706434 | tr_TR |
dc.date.accessioned | 2022-06-10T06:39:03Z | |
dc.date.available | 2022-06-10T06:39:03Z | |
dc.date.issued | 2015-04 | |
dc.description.abstract | Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF. Patients enrolled in studies GS-US-174-0102 and GS-US-174-0103 who had baseline liver biopsy-diagnosed cirrhosis and entered the open-label phase of the studies were included in the virologic and serologic analyses. Patients (both HBeAg positive and negative) with paired liver biopsies at baseline and 5 years (N = 348) were included in a histologic analysis. After 5 years on study, comparing patients with and without baseline cirrhosis, respectively: 99.2 and 98.0 % achieved virologic response (hepatitis B viral load < 69 IU/ml) (p = 0.686); 79.7 and 81.9 % had normal serum levels of alanine aminotransferase (p = 0.586); 4.0 and 1.2 % developed hepatocellular carcinoma (p = 0.044). In HBeAg-positive patients with and without baseline cirrhosis, HBsAg loss occurred in 14.4 and 8.3 % of patients, respectively (p = 0.188). One HBeAg-negative patient had HBsAg loss. This represents the largest analyses to date of CHB patients with sequential liver biopsies demonstrating that treatment with TDF for up to 5 years is associated with favorable virologic, serologic, and histologic outcomes, regardless of baseline cirrhosis status. Notably, histologic improvement was observed in the majority of cirrhotic and noncirrhotic patients. | e |
dc.description.sponsorship | Gilead Sciences | en_US |
dc.description.sponsorship | Robert W. Storr bequest | en_US |
dc.description.sponsorship | University of Sydney | en_US |
dc.description.sponsorship | National Health and Medical Research Council (NHMRC) of Australia (1053206) | en_US |
dc.description.sponsorship | Sydney West Translational Cancer Research Centre Partner Program - Cancer Institute NSW | en_US |
dc.identifier.citation | Buti, M. vd. (2015). "Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years". Hepatology International, 9(2), 243-250. | en_US |
dc.identifier.endpage | 250 | tr_TR |
dc.identifier.issn | 1936-0533 | |
dc.identifier.issue | 2 | tr_TR |
dc.identifier.pubmed | 25788199 | tr_TR |
dc.identifier.scopus | 2-s2.0-84939983283 | tr_TR |
dc.identifier.startpage | 243 | tr_TR |
dc.identifier.uri | https://doi.org/10.1007/s12072-015-9614-4 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s12072-015-9614-4 | |
dc.identifier.uri | http://hdl.handle.net/11452/27027 | |
dc.identifier.volume | 9 | tr_TR |
dc.identifier.wos | 000352480100012 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Hepatology International | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Antiviral agent | en_US |
dc.subject | Chronic hepatitis B | en_US |
dc.subject | Cirrhosis | en_US |
dc.subject | Hepatitis B e antigen | en_US |
dc.subject | Hepatitis B surface antigen | en_US |
dc.subject | Tenofovir disoproxil | en_US |
dc.subject | Hepatocellular-carcinoma | en_US |
dc.subject | Adefovir dipivoxil | en_US |
dc.subject | Follow-up | en_US |
dc.subject | Lamivudine | en_US |
dc.subject | Regression | en_US |
dc.subject | Therapy | en_US |
dc.subject | Disease | en_US |
dc.subject | Level | en_US |
dc.subject | Risk | en_US |
dc.subject | Gastroenterology & hepatology | en_US |
dc.subject.emtree | Alanine aminotransferase | en_US |
dc.subject.emtree | Antivirus agent | en_US |
dc.subject.emtree | Hepatitis B surface antigen | en_US |
dc.subject.emtree | Hepatitis B(e) antigen | en_US |
dc.subject.emtree | Tenofovir | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug effects | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Hepatitis B, chronic | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Liver cell carcinoma | en_US |
dc.subject.emtree | Liver cirrhosis | en_US |
dc.subject.emtree | Liver tumor | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Phase 3 clinical trial | en_US |
dc.subject.emtree | Randomized controlled trial | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Time factor | en_US |
dc.subject.emtree | Virology | en_US |
dc.subject.emtree | Virus load | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Alanine transaminase | en_US |
dc.subject.mesh | Antiviral agents | en_US |
dc.subject.mesh | Carcinoma, hepatocellular | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hepatitis B e antigens | en_US |
dc.subject.mesh | Hepatitis B surface antigens | en_US |
dc.subject.mesh | Hepatitis B, chronic | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Liver cirrhosis | en_US |
dc.subject.mesh | Liver neoplasms | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Tenofovir | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Viral load | en_US |
dc.subject.scopus | Hepatitis B E Antigen; Entecavir; Liver Cell Carcinoma | en_US |
dc.subject.wos | Gastroenterology & hepatology | en_US |
dc.title | Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 | en_US |